Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS
Sponsor: Pfizer
Terminated
Enrollment ceased due to a very low rate of hospitalization or death observed in the standard-risk patient population
A PHASE2/PHASE3 clinical study on COVID-19, this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 14 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Phase: PHASE3 → PHASE2_PHASE3
-
Jan 2023 — Sep 2023 [monthly]
Terminated PHASE3
▶ Show 9 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting · Phase: PHASE2_PHASE3 → PHASE3
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
Phase: PHASE3 → PHASE2_PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting · Phase: PHASE2_PHASE3 → PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting · Phase: PHASE3 → PHASE2_PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Jan 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting · Phase: PHASE2_PHASE3 → PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .